SCHEMBL4604795

SCHEMBL4604795

CCC(=O)Nc1ccc(/C=C/c2cccc(C(F)(F)F)c2)cc1C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM2 O94759 1/20 0.47
KDM4E B2RXH2 1/20 0.47
NFE2L2 Q16236 1/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
LMNA P02545 1/20 0.46
HSP90AA1 P07900 1/20 0.46
MAPT P10636 1/20 0.46
PKM P14618 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
HTT P42858 2/20 0.46
THRB P10828 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
AKR1C3 P42330 1/20 0.45
AKR1C2 P52895 1/20 0.45
MPO P05164 3/20 0.45
GRIK1 P39086 1/20 0.45
TRPA1 O75762 1/20 0.44
TRPM8 Q7Z2W7 1/20 0.44
P4HB P07237 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4604797 1.00 TRPM2 (0.47) TRPM2KDM4ENFE2L2MEN1KMT2A
SCHEMBL4605307 0.86 IGF2BP2 (0.47) KDM4EMEN1KMT2ALMNAPKM
SCHEMBL4605305 0.86 IGF2BP2 (0.47) KDM4EMEN1KMT2ALMNAPKM
SCHEMBL4604659 0.85 ADORA3 (0.54) TRPM2KDM4EMEN1KMT2ALMNA
SCHEMBL4604654 0.85 ADORA3 (0.54) TRPM2KDM4EMEN1KMT2ALMNA
SCHEMBL1828401 0.85 PLK1 (0.43) TRPM2KDM4EMEN1KMT2AMAPT
SCHEMBL1827616 0.85 APP (0.43) TRPM2KDM4EMEN1KMT2AMAPT
SCHEMBL1828407 0.85 PLK1 (0.43) TRPM2KDM4EMEN1KMT2AMAPT
SCHEMBL1827622 0.85 APP (0.43) TRPM2KDM4EMEN1KMT2AMAPT
SCHEMBL1826224 0.84 ALDH1A1 (0.46) KDM4EMEN1KMT2AMAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1914152-B New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB 2010-06-09 CN disclosed
EP-1720825-B1 ANTHRANILIC ACID DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE AS DHODH INHIBITORS ACTIVE BIOTECH AB (SE) 2008-07-09 EP disclosed
CN-1914152-A New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2007-02-14 CN disclosed
EP-1720825-A1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF Active Biotech AB (SE) 2006-11-15 EP disclosed
US-7074831-B2 Compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2006-07-11 US disclosed
US-20050187297-A1 New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2005-08-25 US disclosed
WO-2005075410-A1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF ACTIVE BIOTECH AB (SE) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187297-A1 New compounds, methods for their preparation and use thereof MALT1, TPMT, FUCA1 TRPM2 4278/4885KDM4E 2898/4885NFE2L2 1096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.